

Methodological Note for Blue Earth Diagnostics Ltd 01 Jan 2023 to 31 Dec 2023

Blue Earth Diagnostics (BED) Ltd has followed the recommendations of the ABPI in the disclosure guidelines for Transfer of Value (ToV) to Healthcare Professionals (HCP), Healthcare Organisations (HCO), Patient Organisations (PO) and members of the public. The terminology for various types of ToV is consistent with the meaning of those transactions as defined in the ABPI Code. Disclosure for 2023 includes the disclosure for Blue Earth Therapeutics (BET) sister company of Blue Earth Diagnostics.

Tax Considerations

All payments to HCOs and HCPs are made in full to the recipients. It is the responsibility of the recipients to declare payments to the HMRC for tax purposes. All payments are made inclusive of VAT (where relevant).

Currency Conversion

Where payment is made to the recipient or on behalf of the recipient the prevailing exchange rate at the time of payment is used.

Multi-year Contracts

All contracts with HCPs run on an annual basis. In the UK, no multi-year contracts are in place.

Over-the-Counter Transfers of Value

BED Ltd and BET have no over-the-counter transfers of value.

Medical Device Transfers of Value

BED Ltd and BET do not have any medical devices included in the transfer of value.

Non-Monetary Transfer of Value

No activities and arrangements qualified as non-monetary ToVs in 2023.

R&D Transfer of Value

The ToV for R&D conducted by BED Ltd and BET to the UK entities in 2023 is zero.

2023 Consent on Declaration

All UK HCPs have consented to the individual disclosure of ToV.

Working with Patient Organisations and members of the Public

No transfer of value or payment was made to the UK POs and the UK members of the public including patients and journalists in 2023.

Working with Other Pharmaceutical Companies

BED Ltd or BET did not work jointly with other pharmaceutical companies and therefore all declarations made for ToV are solely for BED Ltd and BET.

----- END -----